Navigation Links
Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Date:4/21/2008

EDISON, N.J., April 21 /PRNewswire/ -- Nostrum, a privately-held company based in Edison, New Jersey, announced today that it has successfully completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix subsidiary, based in Singapore, is developing this therapeutic protein drug under Nostrum's license from the Institute of Microbial Technology, Chandigarh, India, which Nostrum obtained in July 2006.

SMRX11 is an engineered plasminogen activating hybrid protein produced by recombinant DNA technology. The hybrid protein activates plasminogen only in the presence of a blood clot. In the absence of the blood clot protein, Fibrin, SMRX11 displays no plasminogen activation. This unique product therefore potentially avoids the adverse reactions currently faced by thrombolytics in the market. Such adverse reactions include blood thinning and severe bleeding due to a significant degree of spontaneous plasminogen activation even in the absence of Fibrin. Moreover, SMRX11 protects fibrinogen levels in the blood, while dissolving the clot, and hence further lowering the risk of bleeding.

Nostrum recently successfully completed a proof-of-concept study in a non-human primate thrombolysis model that is expected to bear a close relationship with the future studies in humans. In this study, an appropriate dose of SMRX11 was administered as an intravenous bolus and successfully restored femoral arterial blood flow in cynomolgus monkeys following a stable thrombus formation. The animal model utilized has been previously validated on other, FDA approved thrombolytic products such as tPA. More recently, a similar study with SMRX11, which Nostrum conducted in a canine thrombolysis model, has confirmed the results observed in the primate study. "We have seen promising results in this primate model. We were clearly able to demonstrate the utility of SMRX11. Further studies will be c
'/>"/>

SOURCE Nostrum Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a ... use in portable vaporizers, which contains CBD, or ... cannabis, cannabidiol offers consumers a THC-free product made ... vaporizer technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... different compounds which are currently known, two of ...
(Date:7/11/2014)... , July 11, 2014 Patient engagement ... and, consequently, organizations are turning to an assortment ... As part of this evolving approach to ... educate, communicate and engage patients throughout their experiences ... patient empowerment. By mapping the patient journey and ...
(Date:7/11/2014)... 2014 The consumer marketing playbook and ... sectors to better identify winning tools and techniques. ... with and understand consumers, as new technologies are ... purchasing decisions. According to recent ... area where organizations can observe a deep pool ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... LAGUNA HILLS, Calif., Oct. 6 Minnow Medical, Inc., ... thermoplasty for the treatment of in-stent restenosis and other ... veteran medical device executives. Prabodh Mathur ... K. Handley has been named vice president of quality, ...
... Oct. 6 Ferring Pharmaceuticals Inc. today announced ... trials of LYSTEDA™ (tranexamic acid) tablets for cyclic ... of the peer-reviewed journal, Obstetrics & Gynecology ... significantly reduced menstrual blood loss from baseline, and ...
Cached Medicine Technology:Minnow Medical Bolsters Management Team 2Minnow Medical Bolsters Management Team 3Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 2Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 3Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 4
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... people with sex addiction, pornography affects the brain in ... addicts as they consume drugs, a new study finds. ... patients who have compulsive sexual behavior and healthy volunteers. ... Dr. Valerie Voon, of the University of Cambridge in ... research involved 19 men with sex addiction and a ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- U.S. health officials ... were exposed to live anthrax during a safety mishap ... Control and Prevention officials have announced a moratorium on ... high-level government labs. In a report issued Friday, ... to make sure a similar incident doesn,t occur again. ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional Foods, ... Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, Bifidobacteria, ... ” defines and segments the global probiotics market ... value of probiotic products and ingredients. The report ... the global market with an analysis of trends, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... of data across the Network will help physicians ... Wash., March 17 Virtua Health, a four-hospital ... process improvement, has selected Microsoft Amalga, the unified ... give physicians critical information and insight that help ...
... According to Deloitte SurveyWASHINGTON, March 17 As health care ... of consumers have expressed discontent with the status quo, rating ... A quarter of consumers have skipped care when they were ... done so because they simply could not afford it, were ...
... 17 FRIED LICE: "You don,t have to be such a ... manufacturing company, is set to introduce the latest in delousing technology. ... Disease Control "CDC" website. The guidelines are clear in stating: "to ... of 130 degrees." Lice Safe was able to adapt a ...
... China, March 17 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a leading,developer and distributor of ... medicines (TCM), nutritional and dietary supplements, and,medical ... it will conduct,a conference call at 9:00 ...
... as they perform together , , TUESDAY, March 17 (HealthDay ... harmonize along with the music, according to new European ... of eight pairs of guitarists as they played a ... The study found that brain-wave similarities within and between ...
... costs and prevent preterm births, , , TUESDAY, March 17 (HealthDay ... company,s health insurance for a premature baby could cover the ... new report from the March of Dimes claims. , ... average $4,551, of which about $3,800 is covered by employer ...
Cached Medicine News:Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 2Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 3Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 4Health News:Virtua Health Selects Microsoft Amalga to Help Improve Patient Care 5Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 2Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 3Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 4Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 5Health News:Need for Health Care Reform Escalates; One in Four Americans Skip Care When Sick or Injured 6Health News:Lice Safe Introduces Licen Tool 2Health News:China Medicine Announces Conference Call to Discuss Fourth and Fiscal Year 2008 Results 2Health News:Musicians' Brain Waves Are Also in Tune 2Health News:Tiniest Babies Carry Biggest Costs 2Health News:Tiniest Babies Carry Biggest Costs 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: